While the previously discussed studies provide preliminary evidence for MEK inhibitor activity against glucocorticoid-resistant relapsed B-ALL, further studies are needed to assess the effectiveness of MEK inhibition in B-ALL patients. The gene discussed is MAP2K7; the disease is acute lymphoblastic leukemia.